Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas

Trial Title: Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas

NCT ID: NCT06623201

Condition: Basal Cell Carcinoma (BCC)

Conditions: Official terms:
Carcinoma
Carcinoma, Basal Cell
Basal Cell Nevus Syndrome
Aminolevulinic Acid

Conditions: Keywords:
Basal cell carcinoma
Levulan
PDT

Study type: Interventional

Study phase: Phase 1

Overall status: Not yet recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Intervention model description: Open-label study where all participants receive the same treatment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: aminolevulinic acid HCL (ALA)
Description: Prior to ALA application, the areas will be cleaned with alcohol and debrided gently with prep tape. ALA will then be applied to each of the study lesions and allowed to incubate for 3 hours with occlusion prior to the PDT.
Arm group label: Blue-Light Photodynamic Therapy and Sonidegib

Intervention type: Device
Intervention name: BLU-U device model 4170E
Description: Participants will be subjected to dose illumination with blue light (BLU-U Model 4170E) at a power fluence of 20 mW/cm2 for a total time of 16 minutes and 40 seconds (1,000 seconds). This will result in a total light delivery dose of 20 J/cm2.
Arm group label: Blue-Light Photodynamic Therapy and Sonidegib

Summary: This research study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions. Basal cell carcinoma lesions are typically treated by freezing the lesion or surgically removing the lesion. These types of treatment can cause scarring. Photodynamic therapy uses light along with a drug applied to the skin to kill the cancer cells and cause them to break apart. The light used can cause the skin to feel warm, but does not cause scarring.

Detailed description: Blue light PDT has shown some success in treating BCCs, but more research is needed to evaluate this treatment modality further. The objective of this study is to evaluate the safety and efficacy of using photodynamic Therapy with Sonidegib for the treatment of multiple nodular basal cell carcinomas. Participants who meet eligibility criteria at baseline will receive Sonidegib 200 mg by mouth every day for 3 months. Participants will undergo three PDT sessions with topical application of ALA at Day 7, Day 30, and Day 90. The drug applied to the skin before the light treatment is an FDA approved drug called Levulan and has no known side effects. The light used to treat the lesion is blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator (Levulan-PDT). This treatment regimen is approved by the FDA to treat actinic keratoses, but is not approved to treat basal cell carcinoma. Use of the light can feel warm and may sting. Sonidegib (Odomzo) is a compound that was approved by the US Food and Drug Administration in July 2015 as a treatment option for BCC. Patients on Sonidegib may experience leg cramps, taste disturbance, or alopecia

Criteria for eligibility:
Criteria:
Patients will be included in the study based on the following criteria: 1. Male or non-childbearing potential females, at least 18 years of age (Female patients who meet at least one of the following criteria are defined as women of non-childbearing potential) - ≥ 50 years old and naturally amenorrhea for ≥ 1 year - Permanent premature ovarian failure confirmed by specialist gynecologist - Previous bilateral salpingo-oophorectomy or hysterectomy - XY karyotype, Turner's syndrome, or uterine agenesis 2. Diagnosis of BCC with at least 3 nodular lesions that measure 0.5 cm to 5 cm in diameter, located on the head and neck, trunk or extremities. 3. Diagnosis must be confirmed clinically at baseline with 1-2 lesions having been biopsied no sooner than 2 weeks prior to treatment. 4. Patients who may have high burden of disease ie large lesions, who are non-surgical candidates or who refuse surgery. 5. Non-surgical candidates, who may be able to undergo resection of selected single, individual lesion, but may not tolerate extensive surgery, may have many co morbidities, may be prone to complications. 6. Patients in whom surgery or radiation therapy may be impractical 7. Primary lesions may be acceptable for enrollment 8. Within normal limit hematopoietic capacity, hepatic and renal function. Values outside those limits may be allowed at the discretion of the PI, if they are determined as not clinically significant 9. Evidence of a personally signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial. 10. Ability to understand and the willingness to sign a written informed consent document in English 6.2 Exclusion Criteria Patients will be excluded from the study based on the following criteria: 1. Women of childbearing potential 2. Basal cell carcinomas of aggressive subtypes (infiltrative, morpheaform, micronodular) 3. Any BCC that may require Mohs surgery for definitive control 4. Subjects with porphyria's or known hypersensitivity to porphyrins 5. Subjects with known photosensitivity diseases 6. Subjects previously treated with a systemic photosensitizer within 4 months of screening date 7. Subjects who desire to get pregnant a female of childbearing potential within the next 1.5 years 8. Uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 9. Life expectancy less than one year 10. Inability or unwillingness to swallow capsules 11. Have a history of alcohol of substance abuse, unless in full remission for greater than 6 months prior to the screening visit (Day 0) when the consent form is signed. 12. Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses. 13. Having used any of the following treatment within 6 months before the baseline visit: - hedgehog pathway inhibitor, biologics, or chemotherapy - topical chemotherapy agents including Imiquimod, fluorouracil,) to the selected treatment lesion sites within 3 weeks 14. Currently undergoing treatment with photodynamic therapy within 3 weeks before baseline visit 15. Subjects who have received any type of solid organ transplant 16. Subjects taking immunosuppressive medications at the screening visit. 17. Participation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before the screening visit and/or during study participation. Subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study. 18. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. 19. Subjects unable or unwilling to comply with the study visit schedule and requirements of the study 20. Subjects unable to speak and read the English language 21. A subject who, in the opinion of the sponsor-investigator will be uncooperative or unable to comply with study procedures.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Medical Dermatology Specialists

Address:
City: Phoenix
Zip: 85006
Country: United States

Contact:
Last name: Kayla Heraty

Phone: 602-354-5770

Phone ext: 4276
Email: kheraty@usdermpartners.com

Investigator:
Last name: Nathalie Zeitouni, MD
Email: Principal Investigator

Start date: December 1, 2024

Completion date: December 1, 2026

Lead sponsor:
Agency: Nathalie Zeitouni
Agency class: Other

Source: US Dermatology Partners, Phoenix

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06623201